Background: International travel poses unique health risks for individuals with diabetes. This study explored their travel patterns, preparations, and morbidity, as well as identify factors influencing pre-travel health-seeking behavior from primary healthcare providers.
Methods: This cross-sectional, questionnaire-based study recruited adults with diabetes who had traveled internationally within the past 12 months. Data on sociodemographic and clinical characteristics, travel patterns, preparations, and travel-associated morbidity were collected via questionnaires and electronic medical records. Multivariate logistic regression analyses were conducted to identify predictors of patients informing physicians about travel plans.
Results: Among 250 participants (median age: 65 years [57-69]; median HbA1c: 7.1 % [6.6-7.9]), 16.4 % were on insulin therapy. The median travel duration was 6 days (5-10), with a median of one time zone crossed. Insulin-treated individuals tended to plan shorter trips to closer destinations than their non-insulin-treated counterparts. While 70.8 % of participants carried medicines for acute illness, only 10.8 % informed their primary care physicians about travel plans, and 11.2 % experienced travel-associated morbidity, including acute illness, falls, and hypoglycemia. Predictors of informing physicians about travel plans included travel duration exceeding ten days (OR: 4.87, 95 % CI: 1.34-17.63), insulin therapy (OR: 4.37, 95 % CI: 1.21-15.80), taking preventive measures against hypoglycemia during travel (OR: 3.40, 95 % CI: 1.26-9.14), and good antidiabetic medication adherence (OR: 2.96, 95 % CI: 1.10-7.96).
Conclusions: This study underscored the impact of diabetes self-care practices on pre-travel health-seeking behavior and demonstrated how insulin therapy shapes travel patterns, highlighting the need for reinforced self-management skills and targeted pre-travel guidance, especially for insulin-treated patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tmaid.2025.102828 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Methylation Profiles Differ According to Clinical Characteristics in Well-Differentiated Neuroendocrine Tumors of the Lung.
Endocr Pathol
March 2025
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Neuroendocrine tumors (NET) of the lung constitute a rare entity of primary lung malignancies that often exhibit an indolent clinical course. Epigenetics-related differences have been described previously for lung NET, but the clinical significance remains unclear. In this study, we performed genome-wide methylation analysis using the Infinium MethylationEPIC BeadChip technology on FFPE tissues from lung NET treated at two academic centers.
View Article and Find Full Text PDFUncovering the surge: dengue fever on the rise.
Front Epidemiol
February 2025
Department of Internal Medicine, Howard University, Washington, DC, United States.
Introduction: Dengue fever, traditionally a tropical disease, has shown a notable increase in incidence within the United States over recent decades. This paper focuses on the increase in dengue fever cases in Maryland during increasing temperature and humidity and the expanding geographical range of Aedes mosquitoes, the primary vectors for dengue virus transmission.
Methods: Electronic health data was used to identify patterns in dengue incidence from 2014 to 2024.
Access to Healthcare Among Tribal Population in India: A Cross-Sectional Household Survey.
Int J Health Plann Manage
March 2025
Division of Socio-Behavioural, Health Systems & Implementation Research, Indian Council of Medical Research, New Delhi, India.
This study addresses significant healthcare access challenges faced by India's 104 million-strong tribal population, who are among the most disadvantaged and typically live in hilly rural and remote areas with poor health infrastructure and resources. The study aims to examine healthcare access patterns in six tribal areas, focussing on primary health centres (PHCs), to develop a strategy that improves healthcare service accessibility, quality, and utilization for tribal communities. Data were collected from 9837 participants from 24 PHC areas across six states.
View Article and Find Full Text PDFPharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's disease.
Alzheimers Res Ther
March 2025
Department of Biomedical Engineering, University of California, Irvine, CA, USA.
Background: Nicotinamide, a form of B3 vitamin, is an NAD precursor that reduces pTau levels via histone deacetylase inhibition in murine models of Alzheimer's disease (AD). A recent phase 2a randomized placebo-controlled trial tested high-dose oral nicotinamide for the treatment of early AD. While nicotinamide demonstrated good safety and tolerability, it did not significantly lower CSF pTau, the primary biomarker endpoint of the study.
View Article and Find Full Text PDFToward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data.
Orphanet J Rare Dis
March 2025
Peripheral Nervous System and Muscle Department, Reference Center for Neuromuscular Disorders, Pasteur 2 Hospital, Centre Hospitalier, Universitaire de Nice, Nice University Hospital, SNPM - Hôpital Pasteur 2 - 30 voie Romaine, 06001, Nice CEDEX, France.
Background: Myasthenia gravis (MG) is a rare autoimmune disorder. Several new treatment concepts have emerged in recent years, but access to these treatments varies due to differing national reimbursement regulations, leading to disparities across Europe. This highlights the need for high-quality data collection by stakeholders to establish MG registries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!